Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric Crohn's disease platform study of guselkumab
MOH_2024-01-16_013110Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (5 arms), sponsored by Janssen Pharmaceutical. Started Dec 2023; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2024-01-16_013110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-16_013110.